Systemic Treatment of Fabry Disease Using a Novel AAV9 Vector Expressing α-Galactosidase A

Abstract excerpt

Fabry disease is a rare X-linked disorder affecting α-galactosidase A, a rate-limiting enzyme in lysosomal catabolism of glycosphingolipids. Current treatments present important limitations, such as low half-life and limited distribution, which gene therapy can overcome. The aim of this work was to test a novel adeno-associated viral vector, serotype 9 (AAV9), ubiquitously expressing human α-galactosidase A to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lysosomal Storage Disorders Research
• Share to Neurogenetic and Muscular Disorders Research
• Share to Trypanosoma species research and implications